rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

SELLAS Life Sciences Group, Inc.

SLS · Nasdaq

Health CareBiotechnologyLeading

SLS stood above a rising 150-day average in 48 of the last 52 weekly readings, including each of the last 46 weeks. It is 9.9% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
46 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$101K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
182 (+34)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$97KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders182+34 on the quarter
New · exited62 · 28
Reported value$1.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202615,070,302$222.4M+2,871,892+23.5%
STATE STREET CORPadded · filed 7 Aug 202612,996,558$191.8M+4,600,202+54.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20268,226,105$121.4M+700,176+9.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,884,175$72.1M+971,569+24.8%
Anson Funds Management LPnew · filed 13 Aug 20264,500,000$66.4M+4,500,000
JONES FINANCIAL COMPANIES LLLPadded · filed 14 Aug 20262,304,561$28.6M+629,484+37.6%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20262,161,099$31.9M+698,293+47.7%
SUSQUEHANNA INTERNATIONAL GROUP, LLPadded · filed 14 Aug 20262,050,597$30.3M+1,653,541+416.5%
NORTHERN TRUST CORPadded · filed 13 Aug 20261,619,928$23.9M+343,944+27.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 20261,335,166$19.7M+132,327+11.0%
31 Mar 2023 – 30 Jun 2026
24100176Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Angelos M. Stergiou Company insiderPresident and CEO · last 16 Jun 20260 · 3
David A. Scheinberg Company insiderDirector · last 7 Jan 20260 · 0
Dragan Cicic Company insiderSVP, Chief Development Officer · last 7 Jan 20260 · 0
Jane Wasman Company insiderDirector · last 7 Jan 20261 · 0
John Thomas Burns Company insiderCFO · last 7 Jan 20260 · 2
John Varian Company insiderDirector · last 7 Jan 20260 · 0
Katherine Bach Kalin Company insiderDirector · last 7 Jan 20262 · 0
Robert L. Van Nostrand Company insiderDirector · last 7 Jan 20261 · 0
Barbara A. Wood Company insiderEVP, Gen. Counsel, Corp. Sec. · last 22 Jan 20240 · 2
Robert Francomano Company insiderChief Commercial Officer · last 22 Jan 20240 · 0
Nicholas J. Sarlis Company insiderChief Medical Officer and SVP · last 14 Mar 20190 · 0
Stephen F. Ghiglieri Company insiderDirector · last 14 Mar 20190 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-39.6%
Share count trendFY 2025 · to 18 Mar 202617.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$71.8M

Analyst forecasts

No analyst forecasts yet.